STAAR SURGICAL CO (STAA): Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
STAAR SURGICAL CO (STAA) filed an SEC Form 8-K — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers. EX-10.4 5 staa-ex10_4.htm EX-10.4 EX-10.4 Exhibit 10.4 STAAR SURGICAL COMPANY AMENDED AND RESTATED OMNIBUS EQUITY INCENTIVE PLAN STOCK OPTION GRANT NOTICE STAAR Surgical Company, a Delaware corporation, (the “ Company ”), pursuant to its Amended and Restated Omnibus Equity Incent
How this was made
The 30-second read
Why it matters
This is primarily governance and compensation disclosure. It may marginally influence expectations about retention and incentive alignment, but it does not provide new financial performance, product, or regulatory information.
Market read
Traders get new, specific option-grant terms (exercise price, share count, and VWAP hurdles), but no new business catalyst.
What to watch
Traders may overreact to the hurdle prices; the more relevant drivers would be any concurrent executive changes, trial updates, or guidance, none of which are present in the provided text.
Background
The 8-K item 5.02 includes an exhibit describing a stock option grant under STAAR Surgical’s Amended and Restated Omnibus Equity Incentive Plan, including performance-based vesting tied to 60-day VWAP thresholds.
Ticker impact
STAAR Surgical disclosed an 8-K exhibit granting Deborah Andrews a stock option with $50/$75/$100 60-day VWAP performance hurdles and defined vesting/forfeiture terms.
Low likelihood of a sustained price move solely from this option-grant disclosure; any reaction is likely limited to short-term sentiment around compensation terms.
The disclosure is an SEC 8-K exhibit describing option grant mechanics (exercise price, vesting tranches, performance hurdles, and termination forfeiture). It does not include financial results, operational updates, or new regulatory/contract events.
Market effects
Limited sector read-through; equity-compensation plan mechanics are common and not indicative of medical device demand or pipeline changes.
None indicated.
None indicated.
Counterpoint
Performance hurdles tied to higher VWAP levels could be interpreted as management signaling confidence in future stock performance, but the disclosure alone does not confirm operational progress.
Key entities
- issuerSTAAR Surgical Company
Delaware corporation filing the 8-K and granting the option under its equity incentive plan.
- participantDeborah Andrews
Named option recipient; grant date Aug 14, 2026 with specified vesting and performance hurdles.
